Teresa Soler
Overview
Explore the profile of Teresa Soler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marco V, Garcia F, Rubio I, Soler T, Ferrazza L, Roig I, et al.
Rev Esp Patol
. 2021 Sep;
54(4):242-249.
PMID: 34544554
Adenoid cystic carcinoma of the breast (ACCB) is a rare triple negative tumor (TNT) with an excellent prognosis in most cases. Three different histologic types are recognized: classic ACCB, solid...
2.
Ortega Exposito C, Falo C, Pernas S, Perez Carton S, Gil Gil M, Ortega R, et al.
Breast Cancer Res Treat
. 2021 Jun;
189(1):111-120.
PMID: 34089119
Purpose: To report the outcomes of implementing the ACOSOG Z0011 and AMAROS trials relevant to clinical practice, and to define target groups in whom to avoid or recommend axillary radiotherapy...
3.
Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montoli E, et al.
Breast Cancer Res Treat
. 2020 Oct;
185(3):657-666.
PMID: 33068198
Purpose: To find a group of cN2 patients or patients with high axillary burden who become ypN0 after neoadjuvant chemotherapy (NACT) and who may benefit from avoiding a lymphadenectomy. Methods:...
4.
Fernandez-Gonzalez S, Falo C, Pla M, Verdaguer P, Nunez D, Guma A, et al.
Breast J
. 2020 Feb;
26(5):888-896.
PMID: 32052521
A pathologic complete response (pCR) in the axilla occurs in 30%-40% of patients with initially node-positive breast cancer after neo-adjuvant chemotherapy (NACT). Debate persists about whether to perform systematic axillary...
5.
Cisneros-Barroso E, Losada-Lopez I, Gonzalez-Moreno J, Buades J, Ferrer-Nadal A, Ripoll-Vera T, et al.
Amyloid
. 2019 Jul;
26(sup1):59-60.
PMID: 31343326
No abstract available.
6.
Garcia-Tejedor A, Guma A, Soler T, Valdivieso A, Petit A, Contreras N, et al.
Radiology
. 2018 Aug;
289(2):317-324.
PMID: 30129904
Purpose To compare the safety and efficacy of US-guided percutaneous radiofrequency ablation (RFA) as a local treatment for breast cancer with that of lumpectomy. Materials and Methods A prospective, randomized...
7.
Ruiz de Garibay G, Mateo F, Stradella A, Valdes-Mas R, Palomero L, Serra-Musach J, et al.
Dis Model Mech
. 2018 Apr;
11(5).
PMID: 29666142
Understanding the mechanisms of cancer therapeutic resistance is fundamental to improving cancer care. There is clear benefit from chemotherapy in different breast cancer settings; however, knowledge of the mutations and...
8.
Zhang X, Chiang H, Wang Y, Zhang C, Smith S, Zhao X, et al.
Nat Commun
. 2018 Mar;
9:16211.
PMID: 29600804
This corrects the article DOI: 10.1038/ncomms15908.
9.
Fernandez-Gonzalez S, Falo C, Pla M, Pernas S, Bajen M, Soler T, et al.
Clin Breast Cancer
. 2017 Oct;
18(1):71-77.
PMID: 29030106
Background: In patients with breast cancer who are candidates for neoadjuvant therapy (NAT), the timing of when to perform sentinel lymph node biopsy (SLNB) remains under discussion. The aim of...
10.
Zhang X, Chiang H, Wang Y, Zhang C, Smith S, Zhao X, et al.
Nat Commun
. 2017 Jun;
8:15908.
PMID: 28649985
Most BRCA1-associated breast tumours are basal-like yet originate from luminal progenitors. BRCA1 is best known for its functions in double-strand break repair and resolution of DNA replication stress. However, it...